<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21088" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bacterial Endocarditis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vilcant</surname>
            <given-names>Viliane</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hai</surname>
            <given-names>Ofek</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Viliane Vilcant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ofek Hai declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21088.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Bacterial endocarditis refers to infection of the endocardial surface of the heart. It usually involves heart valves, but it can occur on the endocardium or intracardiac devices. Acute endocarditis is a febrile illness that rapidly damages cardiac structures and spreads hematogenously which can progress to death within weeks if not treated. Subacute endocarditis has a slower disease process and may be present for weeks to months with gradual progression unless complicated by major embolic event or ruptured structure. This activity reviews the cause, pathophysiology, and presentation of bacterial endocarditis and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of bacterial endocarditis.</p></list-item><list-item><p>Review the presentation of a patient with bacterial endocarditis.</p></list-item><list-item><p>Summarize the treatment and management options available for bacterial endocarditis.</p></list-item><list-item><p>Explain the interprofessional team strategies for improving care coordination and communication regarding the management of patients with bacterial endocarditis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21088&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21088">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21088.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Bacterial endocarditis refers to infection of the endocardial surface of the heart. It usually involves heart valves, but it can occur on the endocardium or intracardiac devices.</p>
        <p>There are two types:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute endocarditis is a febrile illness that rapidly damages cardiac structures and spreads hematogenously which can progress to death within weeks if not treated.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Subacute endocarditis has a slower disease process and may be present for weeks to months with gradual progression unless complicated by major embolic event or ruptured structure.<xref ref-type="bibr" rid="article-21088.r1">[1]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21088.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Most cases are caused by viridans streptococci, <italic toggle="yes">Streptococcus gallolyticus</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, coagulase-negative staphylococci, HACEK organisms (<italic toggle="yes">Haemophilus</italic>, <italic toggle="yes">Aggregatibacter</italic>, <italic toggle="yes">Cardiobacterium</italic>, <italic toggle="yes">Eikenella</italic>, <italic toggle="yes">Kingella</italic>), and enterococci. Rarer organisms include pneumococci, <italic toggle="yes">Candida</italic>, gram-negative bacilli, and polymicrobial organisms.<xref ref-type="bibr" rid="article-21088.r1">[1]</xref></p>
      </sec>
      <sec id="article-21088.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In developed countries, the incidence of endocarditis ranges from 2.6 to 7 cases per 100,000 population per year. The median age of patients with endocarditis is 58 years.</p>
        <p>
<bold>Risk factors</bold>
</p>
        <p>Age greater than 60 years, male gender, injection drug use, history of prior infective endocarditis, poor dentition or dental procedure, presence of a prosthetic valve or intracardiac device, history of valvular disease (rheumatic heart disease, mitral valve prolapse, aortic valve disease, mitral regurgitation, etc), congenital heart disease (aortic stenosis, bicuspid aortic valve, pulmonary stenosis, ventricular septal defect, patent ductus arteriosus, coarctation of the aorta, and tetralogy of Fallot), indwelling intravenous catheter, immunosuppression, hemodialysis patients.<xref ref-type="bibr" rid="article-21088.r2">[2]</xref></p>
      </sec>
      <sec id="article-21088.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Endothelial injury allows for either direct infection by virulent organisms or the development of uninfected platelet-fibrin thrombus which becomes a nidus for transient bacteremia, except in the case of <italic toggle="yes">S. aureus</italic>, which can infect intact endothelium. These organisms enter the bloodstream from the skin, mucosal surfaces or previously infected sites and adhere to nonbacterial thrombus due to valvular damage or turbulent blood flow. In the absence of host defenses, this organism is allowed to proliferate forming small colonies and shed in the bloodstream. Left-sided infection is much more common than right-sided infection, except among intravenous drug users.<xref ref-type="bibr" rid="article-21088.r3">[3]</xref></p>
      </sec>
      <sec id="article-21088.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Fever is the most common symptom. It can be associated with chills, night sweats, anorexia, weight loss, loss of appetite, malaise, headache, myalgias, arthralgias, abdominal pain, dyspnea, cough, and pleuritic pain.</p>
        <p>Cardiac murmurs are observed in about 85% of patients. Congestive heart failure develops in 30% to 40% of patients usually due to valvular dysfunction. Other signs include cutaneous manifestations such as petechiae or splinter hemorrhages (non-blanching linear reddish-brown lesions under the nail bed).</p>
        <p>Complications include conduction disease (first-degree atrioventricular block, bundle branch block, or complete heart block), ischemia (emboli to the coronary arteries), embolic stroke, intracerebral hemorrhage, brain abscess, septic emboli leading to infarction of the kidneys, spleen, lungs and other organs, hematogenous spread of infection leading to vertebral osteomyelitis, septic arthritis, or psoas abscess and systemic immune reaction such as glomerulonephritis.<xref ref-type="bibr" rid="article-21088.r4">[4]</xref></p>
      </sec>
      <sec id="article-21088.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Definite Infective Endocarditis</bold>
</p>
        <p>Pathologic criteria: Pathologic lesions such as vegetation or intracardiac abscess demonstrating active endocarditis on histology or microorganisms demonstrated by culture or histology of vegetation or intracardiac abscess</p>
        <p>Clinical criteria: Two major clinical criteria or one major and three minor clinical criteria or five minor clinical criteria</p>
        <p>
<bold>Possible infective Endocarditis </bold>
</p>
        <p>One major and one minor clinical criteria or the presence of three minor clinical criteria</p>
        <p>
<bold>Rejected Diagnosis of Infective Endocarditis </bold>
</p>
        <p>If an alternate diagnosis is established, if there is the resolution of clinical manifestations with less than or equal to 4 days of antibiotic therapy, if there is no pathological evidence of infective endocarditis found at surgery or autopsy after antibiotic therapy for&#x000a0;enterococci&#x000a0;4 days, or if clinical criteria for possible or definite infective endocarditis is not met</p>
        <p>
<bold>Major Clinical Criteria:</bold>
</p>
        <p>Positive blood cultures (one of the following):</p>
        <list list-type="bullet">
          <list-item>
            <p>Typical microorganisms for infective endocarditis from two separate blood cultures (<italic toggle="yes">S. aureus</italic>, <italic toggle="yes">Viridans streptococci</italic>, <italic toggle="yes">Streptococcus gallolyticus</italic>, HACEK group), or community-acquired enterococci in the absence of a primary focus) OR</p>
          </list-item>
          <list-item>
            <p>Persistently positive blood culture&#x000a0; with organisms that are typical causes of endocarditis from blood cultures drawn greater than 12 hours apart or all of three or a majority of equal to or greater than 4 separate blood cultures for organisms that are more common skin contaminants OR</p>
          </list-item>
          <list-item>
            <p>Single positive blood culture for<italic toggle="yes"> Coxiella burnetii</italic> or phase I IgG antibody titer greater than 1:800<xref ref-type="bibr" rid="article-21088.r5">[5]</xref><xref ref-type="bibr" rid="article-21088.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Evidence of endocardial involvement (one of the following):</p>
        <list list-type="bullet">
          <list-item>
            <p>Echocardiography positive for oscillating intracardiac mass on a valve or supporting structures or in the path of regurgitant jets, or on implanted material, in the absence of an alternative anatomic explanation or abscess or new partial dehiscence of prosthetic valve</p>
          </list-item>
          <list-item>
            <p>New valvular regurgitation&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Minor Clinical Criteria:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Predisposition: Intravenous drug use or presence of a predisposing heart condition</p>
          </list-item>
          <list-item>
            <p>Fever: Temperature greater than or equal to 38.0 C (100.4 F)</p>
          </list-item>
          <list-item>
            <p>Vascular phenomena: Major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, or Janeway lesions (non-tender erythematous macules on the palms and soles)</p>
          </list-item>
          <list-item>
            <p>Immunologic phenomena: Glomerulonephritis, Osler nodes (tender subcutaneous violaceous nodules mostly on the pads of the fingers and toes, which may also occur on the thenar and hypothenar eminences), Roth spots (exudative, edematous hemorrhagic lesions of the retina with pale centers), or rheumatoid factor</p>
          </list-item>
          <list-item>
            <p>Microbiologic evidence: Positive blood cultures not meeting major criterion or serologic evidence of active infection with organism consistent with infective endocarditis<xref ref-type="bibr" rid="article-21088.r5">[5]</xref><xref ref-type="bibr" rid="article-21088.r3">[3]</xref></p>
          </list-item>
        </list>
        <p><bold>Blood Cultures</bold>&#x000a0;</p>
        <p>At least three sets of blood cultures, separated from one another by at least 1 hour, should be obtained from separate venipuncture sites before initiation of antibiotic therapy. If cultures remain negative after 48 to 72 hours, two or three additional blood cultures should be obtained.</p>
        <p>Culture-negative endocarditis is defined as endocarditis with no definitive microbiologic etiology after at least three independently obtained blood cultures. Up to 14% of patients may have negative blood cultures due to previous antibiotics therapy or due to fastidious organisms such as <italic toggle="yes">Coxiella</italic>, <italic toggle="yes">Legionella</italic>, <italic toggle="yes">Bartonella</italic>, <italic toggle="yes">Mycoplasma</italic>, <italic toggle="yes">Brucella</italic>, <italic toggle="yes">Chlamydia</italic>, and fungi.</p>
        <p>
<bold>Diagnostic Imaging</bold>
</p>
        <p>Echocardiography should be performed in all patients with suspected bacterial endocarditis. In general, transthoracic echocardiography (TTE) is the first diagnostic test; however, transesophageal echocardiography (TEE) has higher sensitivity than TTE and is better for detection of cardiac complications such as abscess, leaflet perforation, and pseudoaneurysm. TTE is inadequate for detecting small vegetations (less than 2 mm), evaluating prosthetic valves and may be technically inadequate due to lung disease or body habitus.</p>
        <p>Patients with a negative TEE for whom the clinical suspicion for IE is high should undergo repeat TEE 7 to 10 days later. Repeat TEE is also warranted after an initial positive TEE if clinical features suggest the new development of an intracardiac complication.</p>
        <p>
<bold>Laboratory Findings</bold>
</p>
        <p>Laboratory data are usually nonspecific. Positive findings may include elevated inflammatory markers (erythrocyte sedimentation rate and/or elevated C-reactive protein), normochromic-normocytic anemia, positive rheumatoid factor, hypergammaglobulinemia, cryoglobulinemia, circulating immune complexes, hypocomplementemia, and false-positive serologic tests for syphilis. Urinalysis may demonstrate proteinuria, microscopic hematuria, and/or pyuria.<xref ref-type="bibr" rid="article-21088.r5">[5]</xref></p>
      </sec>
      <sec id="article-21088.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Empiric antibiotic therapy should cover <italic toggle="yes">Staphylococcus</italic> (methicillin-susceptible and resistant), <italic toggle="yes">Streptococcus</italic>, and <italic toggle="yes">Enterococcus</italic>. Initial treatment with vancomycin and gentamicin should cover a number of organisms prior to the results of blood cultures.</p>
        <p>The duration of therapy depends on the pathogen and site of valvular infection. The duration of therapy should be counted from the first day of negative blood cultures. Most patients are treated parenterally with regimens for up to 6 weeks.</p>
        <p>Patients with relapse of native valve endocarditis following completion of appropriate antimicrobial therapy should receive a repeat course of antibiotics.<xref ref-type="bibr" rid="article-21088.r6">[6]</xref><xref ref-type="bibr" rid="article-21088.r7">[7]</xref><xref ref-type="bibr" rid="article-21088.r8">[8]</xref></p>
        <p>
<bold>Treatment of specific organisms:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Methicillin-sensitive <italic toggle="yes">S. aureus</italic>: nafcillin or oxacillin</p>
          </list-item>
        </list>
        <p>If nonsevere penicillin allergy: cefazolin</p>
        <p>If severe penicillin allergy: vancomycin and daptomycin</p>
        <list list-type="bullet">
          <list-item>
            <p>Methicillin-resistant<italic toggle="yes"> S. aureus</italic> or coagulase-negative staphylococci: vancomycin for 6 weeks</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Viridans streptococci and <italic toggle="yes">S. gallolyticus</italic>: penicillin G or ceftriaxone for 4 weeks.</p>
          </list-item>
        </list>
        <p>If penicillin-resistant: penicillin G for four weeks plus gentamicin for the first two weeks.</p>
        <p>Penicillin allergy: vancomycin&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">S. pneumoniae</italic>: penicillin G, cefazolin, or ceftriaxone for four weeks</p>
          </list-item>
        </list>
        <p>Penicillin allergy: vancomycin&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Enterococcal species: penicillin or ampicillin plus gentamicin for 4 to 6 weeks</p>
          </list-item>
        </list>
        <p>Penicillin allergy: vancomycin plus gentamicin for 6 weeks.</p>
        <list list-type="bullet">
          <list-item>
            <p>Vancomycin-resistant enterococcus:&#x000a0;linezolid or quinupristin-dalfopristin or imipenem&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>HACEK organisms: ceftriaxone, ampicillin or ciprofloxacin for 4 weeks</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21088.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Antiphospholipid syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Atrial myxoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Connective tissue disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fever of unknown origin</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infective endocarditis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intraabdominal infections</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lyme disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Marantic endocarditis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Physical medicine and rehabilitation for systemic lupus erythematosus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Polymyalgia rheumatica</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21088.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of bacterial endocarditis is with an interprofessional team that includes an infectious disease expert, cardiologist, cardiac surgeon, internist, nurse practitioner, and the primary care provider. Once the diagnosis is made the treatment depends on the status of the valve.&#x000a0;</p>
        <p>Empiric antibiotic therapy should cover&#x000a0;<italic toggle="yes">Staphylococcus</italic>&#x000a0;(methicillin-susceptible and resistant),&#x000a0;<italic toggle="yes">Streptococcus</italic>, and&#x000a0;<italic toggle="yes">Enterococcus</italic>. Initial treatment with vancomycin and gentamicin should cover a number of organisms prior to the results of blood cultures.</p>
        <p>The duration of therapy depends on the pathogen and site of valvular infection. The duration of therapy should be counted from the first day of negative blood cultures. Most patients are treated parenterally with regimens for up to 6 weeks.</p>
        <p>Patients with relapse of native valve endocarditis following completion of appropriate antimicrobial therapy should be considered for surgery.<xref ref-type="bibr" rid="article-21088.r6">[6]</xref><xref ref-type="bibr" rid="article-21088.r7">[7]</xref><xref ref-type="bibr" rid="article-21088.r8">[8]</xref>&#x000a0;The prognosis for patients with bacterial endocarditis depends on the age, number of valves infected, comorbidity, number of other organs affected and any neurological deficit.<xref ref-type="bibr" rid="article-21088.r9">[9]</xref><xref ref-type="bibr" rid="article-21088.r10">[10]</xref></p>
      </sec>
      <sec id="article-21088.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21088&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21088">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/bacterial-endocarditis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21088">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21088/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21088">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21088.s12">
        <fig id="article-21088.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Table 1. Etiologic agents of infective endocarditis in the Pediatric population. Contributed by Olga Brea Pena, MD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21088.s13">
        <title>References</title>
        <ref id="article-21088.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dudzinski</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Siedner</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2019</year>
            <month>Mar</month>
            <day>20</day>
            <volume>32</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30760474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiyota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Della Corte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montiero Vieira</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Habchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Della Ratta</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Sundt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Shekar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Muehlschlegel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Body</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Risk and outcomes of aortic valve endocarditis among patients with bicuspid and tricuspid aortic valves.</article-title>
            <source>Open Heart</source>
            <year>2017</year>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>e000545</fpage>
            <pub-id pub-id-type="pmid">28674620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[The clinical and pathological features of patients with infective endocarditis diagnosed at autopsy].</article-title>
            <source>Zhonghua Nei Ke Za Zhi</source>
            <year>2017</year>
            <month>Oct</month>
            <day>01</day>
            <volume>56</volume>
            <issue>10</issue>
            <fpage>725</fpage>
            <page-range>725-728</page-range>
            <pub-id pub-id-type="pmid">29036951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000fc;&#x000e7;&#x000fc;ko&#x0011f;lu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>K&#x00131;l&#x00131;&#x000e7;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Infective endocarditis in two patients with pemphigus vulgaris under multiagent immunosuppressive drug therapy: A rare entity to remember in the differential diagnosis of fever of unknown origin.</article-title>
            <source>Dermatol Ther</source>
            <year>2019</year>
            <month>May</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>e12860</fpage>
            <pub-id pub-id-type="pmid">30758911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El Chami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jibbe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shahouri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bacterial Endocarditis Presenting as Leukocytoclastic Vasculitis.</article-title>
            <source>Cureus</source>
            <year>2017</year>
            <month>Jul</month>
            <day>13</day>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>e1464</fpage>
            <pub-id pub-id-type="pmid">28936376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maskarinec</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Thaden</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Cyr</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Ruffin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Souli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>VG</given-names>
              </name>
            </person-group>
            <article-title>The Risk of Cardiac Device-Related Infection in Bacteremic Patients Is Species Specific: Results of a 12-Year Prospective Cohort.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2017</year>
            <season>Summer</season>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>ofx132</fpage>
            <pub-id pub-id-type="pmid">28852678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spittle</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Muzzin</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>DeWald</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rivera-Hidalgo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Current prescribing Practices for Antibiotic Prophylaxis: A Survey of Dental Practitioners.</article-title>
            <source>J Contemp Dent Pract</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>559</fpage>
            <page-range>559-566</page-range>
            <pub-id pub-id-type="pmid">28713108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sorabella</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Vasan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grbic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kurlansky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Borger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Influence of Staphylococcus aureus on Outcomes after Valvular Surgery for Infective Endocarditis.</article-title>
            <source>J Cardiothorac Surg</source>
            <year>2017</year>
            <month>Jul</month>
            <day>20</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <pub-id pub-id-type="pmid">28728556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yanagawa</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mazine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Spindel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puskas</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Friedrich</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Homograft Versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis: A Systematic Review and Meta-analysis.</article-title>
            <source>Innovations (Phila)</source>
            <year>2018</year>
            <season>May/Jun</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>163</fpage>
            <page-range>163-170</page-range>
            <pub-id pub-id-type="pmid">29912740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21088.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>XB</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>DQ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Risk prediction in infective endocarditis by modified MELD-XI score.</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>1243</fpage>
            <page-range>1243-1250</page-range>
            <pub-id pub-id-type="pmid">29594801</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
